Haopeng Yang

Haopeng Yang

Auto-generated profile, based on publicly available information

Haopeng Yang

Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
GHGuangchun Han
Guangchun Han
QDQing Deng
Qing Deng
MMMario L. Marques-Piubelli
Mario L. Marques-Piubelli
EDEnyu Dai
Enyu Dai
MDMinghao Dang
Minghao Dang
Michael GreenMichael Green
Michael Green
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression. Significance: We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell–intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression. See related commentary by Melnick, p. 374. This article is highlighted in the In This Issue feature, p. 369

4 October 2024 in Science
Verified
Journal Article
Closed access
RSRoman C. Sarott
Roman C. Sarott
SGSai Gourisankar
Sai Gourisankar
BKBasel Karim
Basel Karim
SNSabin Nettles
Sabin Nettles
HYHaopeng Yang
Haopeng Yang
NGNathanael S. Gray
Nathanael S. Gray
Kinases are critical regulators of cellular function that are commonly implicated in the mechanisms underlying disease. Most drugs that target kinases are molecules that inhibit their catalytic activity, but here we used chemically induced proximity to convert kinase inhibitors into activators of therapeutic genes. We synthesized bivalent molecules that link ligands of the transcription factor B cell lymphoma 6 (BCL6) to inhibitors of cyclin-dependent kinases (CDKs). These molecules relocalized CDK9 to BCL6-bound DNA and directed phosphorylation of RNA polymerase II. The resulting expression of pro-apoptotic, BCL6-target genes caused killing of diffuse large B cell lymphoma cells and specific ablation of the BCL6-regulated germinal center response. Genomics and proteomics corroborated a gain-of-function mechanism in which global kinase activity was not inhibited but rather redirected. Thus, kinase inhibitors can be used to context-specifically activate transcription.

17 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMeredith N. Nix
Meredith N. Nix
SGSai Gourisankar
Sai Gourisankar
RSRoman C. Sarott
Roman C. Sarott
BDBrendan G. Dwyer
Brendan G. Dwyer
SNSabin. A. Nettles
Sabin. A. Nettles
GCGerald R. Crabtree
Gerald R. Crabtree
SUMMARY: Developing cancer therapies that induce robust death of the malignant cell is critical to prevent relapse. Highly effective strategies, such as immunotherapy, exemplify this observation. Here we provide the structural and molecular underpinnings for an approach that leverages chemical induced proximity to produce specific cell killing of diffuse large B cell lymphoma, the most common non-Hodgkin’s lymphoma. We develop KAT-TCIPs (lysine acetyltransferase transcriptional/epigenetic chemical inducers of proximity) that redirect p300 and CBP to activate programmed cell death genes normally repressed by the oncogenic driver, BCL6. Acute treatment rapidly reprograms the epigenome to initiate apoptosis and repress c-MYC. The crystal structure of the chemically induced p300-BCL6 complex reveals how chance interactions between the two proteins can be systematically exploited to produce the exquisite potency and selectivity of KAT-TCIPs. Thus, the malignant function of an oncogenic driver can be co-opted to activate robust cell death, with implications for precision epigenetic therapies.

2 July 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GCGuiling Cui
Guiling Cui
MLMarie Ley
Marie Ley
AMAriel E. Mechaly
Ariel E. Mechaly
LBLinh-Chi Bui
Linh-Chi Bui
CMChristina Michail
Christina Michail
FLFernando RODRIGUES LIMA
Fernando RODRIGUES LIMA
In addition to histone acetylation, histone lysine propionylation (such as the H3K18Pr mark) has recently attracted significant attention as a common and abundant modification linking the cellular metabolic state and gene expression. CREB-binding protein (CREBBP) and EP300 are key histone acetyltransferases that play a critical role in gene expression through their catalytic activity. Although CREBBP and EP300 are homologous enzymes with high structural similarities, they exhibit both redundant and specific functions. Dissecting the shared and divergent properties of CREBBP and EP300 is thus important to understand their roles. However, despite the importance of CREBBP, most mechanistic and structural studies have focused on EP300, leaving much less information about CREBBP. Interestingly, recent enzymatic and structural studies have demonstrated that EP300 can also function as a histone propionyltransferase. Using a combination of acyltransferase assays with different acyl-CoA cofactors and with peptides, recombinant histone, or recombinant nucleosomes as substrates, we provide enzymatic evidence that, in addition to its well-documented acetyltransferase activity, CREBBP readily propionylates histone H3 in vitro, notably generating the H3K18Pr mark. Importantly, subsequent cellular studies using CRISPR-Cas9-edited cells further support that CREBBP can act as a histone propionyltransferase in vivo, notably depositing the H3K18Pr mark. Finally, the crystal structures of the human CREBBP histone acetyltransferase domain in complex with propionyl-CoA or in complex with Lys-CoA provide the structural basis for the histone propionyltransferase properties of CREBBP. Taken together, these findings provide new insights into the enzymatic functions of CREBBP and a better understanding of the mechanisms linking cellular metabolism and epigenetic regulation.

20 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B-cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small-molecule inhibitor, ABBV-MALT1, that potently shuts down B-cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition. We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.

25 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RSRoman C Sarott
Roman C Sarott
SGSai P Gourisankar
Sai P Gourisankar
BKBasel Aydon Karim
Basel Aydon Karim
SNSabin Nettles
Sabin Nettles
HYHaopeng Yang
Haopeng Yang
NGNathanael S. Gray
Nathanael S. Gray
Protein kinases are disease drivers whose therapeutic targeting traditionally centers on inhibition of enzymatic activity. Here chemically induced proximity is leveraged to convert kinase inhibitors into context-specific activators of therapeutic genes. Bivalent molecules that link ligands of the transcription factor B-cell lymphoma 6 (BCL6) to ATP-competitive inhibitors of cyclin-dependent kinases (CDKs) were developed to re-localize CDK to BCL6-bound loci on chromatin and direct phosphorylation of RNA Pol II. The resulting BCL6-target proapoptotic gene expression translated into killing of diffuse large B-cell lymphoma (DLBCL) cells at 72 h with EC50s of 0.9 – 10 nM and highly specific ablation of the BCL6-regulated germinal center response in mice. The molecules exhibited 10,000-fold lower cytotoxicity in normal lymphocytes and are well tolerated in mice. Genomic and proteomic evidence corroborated a gain-of-function mechanism where, instead of global enzyme inhibition, a fraction of total kinase activity is borrowed and re-localized to BCL6-bound loci. The strategy demonstrates how kinase inhibitors can be used to context-specifically activate transcription, accessing new therapeutic space.